ClinicalTrials.gg
RecruitingNCT06876090SiGnal-DUpdated Nov 21, 2025

Sarcopenia in Gestational Diabetes

An observational study in Sarcopenia, Gestational Diabetes Mellitus (GDM) and Pregnancy Complications, sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche. Recruiting at 3 sites in 2 countries. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
35 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Sarcopenia with a site in Italy — 29 open to participants now, 32 under way, 1 of them phase 3. Sarcopenia · Italy.

Planned enrollment
14th of 31
200 · median 160
Started
2025
with 5 others
Observational
31 of 70
14 open now
Primary completion
2026-04
later than 16 of 31 live
Registered
57th of 70
by date
Lead sponsor
2 of 70
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche

Among the 70 studies in Sarcopenia with a site in Italy, this one is the 14th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 16 of the 31 other live ones, and was the 57th registered.

Sarcopenia

1,333 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

29 of the 70 studies in Sarcopenia with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 35 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Sarcopenia with a site in Italy, or all of them as a file.
02

Study summary

Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:

  1. To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence;
  2. To identify risk factors for sarcopenia;
  3. To determine sarcopenia impact on pregnancy outcomes, and cognitive function.

During pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia/presarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.

03

Conditions studied

  • Sarcopenia
  • Gestational Diabetes Mellitus (GDM)
  • Pregnancy Complications
  • Adverse Maternal and Neonatal Outcomes
  • Cognitive Function
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women, based on the inclusion and exclusion criteria as outlined above.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At least one among the following conditions:

  • Age equal to or higher than 35 years;
  • (BMI) equal to or higher than 25 kg/m\^2;
  • Glycemia between 5.6 and 6.9 mmol/L before or at the beginning of pregnancy;
  • Fetal macrosomia in previous pregnancy;
  • GDM in previous pregnancy;
  • First-degree family history of diabetes.

Exclusion criteria

Exclusion Criteria:

  • Unmatching of at least one among the inclusion criteria;
  • Twin pregnancy;
  • Presence of any already known disease/disorder possibly affecting muscle mass or function;
  • Neurological or psychiatric diseases;
  • Already known diabetes (e.g., type 1 or type 2 diabetes).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Gestational diabetes (GDM) women

    Diagnostic Test: Sarcopenia tests (for muscle mass, muscle function, physical performance) · Diagnostic Test: Oral Glucose Tolerance Test · Other: Montreal Cognitive Assessment

  • Pregnant women without gestational diabetes (non-GDM)

    Diagnostic Test: Sarcopenia tests (for muscle mass, muscle function, physical performance) · Diagnostic Test: Oral Glucose Tolerance Test · Other: Montreal Cognitive Assessment

Interventions

  • Diagnostic testSarcopenia tests (for muscle mass, muscle function, physical performance)

    We are not aware of any other study performing sarcopenia tests in GDM (or in pregnancy in general), with the aim of assessing sarcopenia prevalence in GDM/pregnancy, and related possible adverse pregnancy outcomes.

  • Diagnostic testOral Glucose Tolerance Test

    The OGTT, in combination with the sarcopenia tests, will allow to explore the relationships between the glucometabolic condition and the muscle quality in the pregnant women, either with GDM or with normal glucose tolerance.

  • OtherMontreal Cognitive Assessment

    The MoCA questionnaire, in combination with the sarcopenia tests, will allow to explore the relationships between the cognitive function the presence of the sarcopenia syndrome in the pregnant women, either with GDM or with normal glucose tolerance.

06

What researchers measure

Primary outcomes

  1. Prevalence of sarcopenia/presarcopenia in pregnant women with and without gestational diabetes

    Time frame: Between week 28 and week 32 of pregnancy

Other outcomes

  1. Identification of pre-gestational factors (obstetric history, pre-pregnancy body weight, dietary and physical activity habits) and gestational factors (body mass index, blood pressure, OGTT values) with risk of sarcopenia

    Pre-gestational data as well as gestational data, as indicated above, will be collected at visit V1 (week 16-18 for women at high GDM risk or week 24-28 for women not at high GDM risk), whereas sarcopenia diagnosis (visit V2) will occur between week 28 and 32 (sarcopenia diagnosis being necessary to indentify, among the indicated pre-gestational and gestational factors, the risk factors for sarcopenia itself).

    Time frame: Between week 16 and week 32 of pregnancy

  2. Assessment of the potential impact of sarcopenia/presarcopenia on pregnancy outcomes (large or small for gestational age, LGA or SGA)

    Time frame: Between week 28 and week 32 of pregnancy

  3. Exploration of the potential relationship between sarcopenia (presence or no presence of sarcopenia) and cognitive function in pregnancy (MoCA questionnaire score)

    The investigators will assess whether the MoCA questionnaire score is different in women with and without sarcopenia.

    Time frame: Between week 28 and week 32 of pregnancy

  4. Assessment of the potential impact of sarcopenia/presarcopenia on pregnancy outcomes (type of delivery)

    Time frame: At the time of delivery

07

Study locations

2 of 3 sites recruiting
  • Department of Obstetrics and Gynaecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna
    Vienna, 1090, Austria
    Recruiting
    • Christian Göbl · Contactchristian.gobl@meduniwien.ac.at · +43 660/65 34 828
    • Christian Göbl · Principal investigator
    • Tina Linder · Sub investigator
    • Sophie Zarotti · Sub investigator
  • Institute of Neuroscience, National Research Council
    Padova, PD 35127, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Department of Clinical and Experimental Medicine, University of Pisa
    Pisa, PI 56124, Italy
    Recruiting
    • Angela Dardano · Contactangela.dardano@unipi.it · +39050995146
    • Angela Dardano · Principal investigator
    • Giuseppe Daniele · Sub investigator
08

References and documents

Publications

  • Dardano A, Daniele G, Gobl CS, Tura A. Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study. BMJ Open. 2026 Mar 2;16(3):e106837. doi: 10.1136/bmjopen-2025-106837. PubMed 41771588 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2026, 11 months after the start.

Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 14, 2025
StartActual
May 28, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06876090
Lead sponsor
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
Responsible party
Andrea Tura (Principal Investigator, Istituto di Neuroscienze Consiglio Nazionale delle Ricerche) — Principal investigator
First posted
Mar 14, 2025
Start date
May 28, 2025
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Nov 21, 2025

Study contacts

Andrea Tura
Contact
andrea.tura@cnr.it
+390498295786
Angela Dardano
Contact
angela.dardano@unipi.it
+39050995146

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion